Patient-Reported Outcomes After Nirmatrelvir in High-Risk Adults With COVID-19
Overview
In a phase 2/3 trial, nirmatrelvir/ritonavir (NMV/r) significantly reduced the median time to return to usual health and activities in high-risk, nonhospitalized adults with symptomatic COVID-19. Patients receiving NMV/r reported shorter duration and severity of symptoms compared with placebo, although no significant differences were observed in work productivity or quality of life measures.
Background
COVID-19 continues to pose a significant burden, especially among older adults and those with comorbidities. Beyond physical illness, COVID-19 adversely affects health-related quality of life (HRQoL) and productivity. Nirmatrelvir, combined with ritonavir (NMV/r), is an oral antiviral approved for treating mild-to-moderate COVID-19 in high-risk patients, shown to reduce hospitalization and death. However, its impact on patient-reported outcomes such as symptom burden, daily activities, and HRQoL had not been fully characterized prior to this study.
Data Highlights
Outcome
NMV/r Median Time (days)
Placebo Median Time (days)
Hazard Ratio (95% CI)
P Value
Return to Usual Health
Not specified (3 days shorter than placebo)
Not specified
1.3 (1.2–1.4)
<.0001
Return to Usual Activities
Not specified (1 day shorter than placebo)
Not specified
1.2 (1.1–1.4)
<.0001
Sustained Resolution of Any Symptoms
Not specified
Not specified
1.2 (1.1–1.3)
=.0002
Sustained Alleviation of Any Symptoms
Not specified
Not specified
1.2 (1.1–1.3)
<.0001
WPAI-COVID-19 and EQ-5D-5L Scores
No significant difference
No significant difference
Not applicable
Not significant
Key Findings
NMV/r treatment reduced median time to return to usual health by 3 days compared with placebo (HR 1.3; P <.0001).
Median time to return to usual activities was shortened by 1 day with NMV/r (HR 1.2; P <.0001).
NMV/r led to significantly faster sustained resolution and alleviation of overall COVID-19 symptoms (HR 1.2; P ≤ .0002).
No significant differences were observed between NMV/r and placebo groups in work productivity (WPAI-COVID-19) or health-related quality of life (EQ-5D-5L) scores through week 24.
Patient-reported outcomes were collected via validated questionnaires including Global Impression Questions, WPAI-COVID-19, and EQ-5D-5L during the 24-week follow-up.
Clinical Implications
NMV/r provides a meaningful reduction in symptom duration and accelerates return to usual health and activities in high-risk, nonhospitalized COVID-19 patients. While improvements in work productivity and quality of life measures were not statistically significant, the faster symptom resolution may reduce patient burden and healthcare utilization. Clinicians should consider NMV/r for eligible patients to improve patient-centered outcomes alongside reducing severe disease risk.
Conclusion
Nirmatrelvir/ritonavir treatment in high-risk adults with symptomatic COVID-19 significantly shortens symptom duration and expedites recovery to usual health and activities. These patient-reported benefits complement the antiviral’s established efficacy in reducing hospitalization and death.
